# Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg

> **NCT01018342** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
- **DRUG:** Macrobid® Capsules 100 mg

## Key facts

- **NCT ID:** NCT01018342
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2002-08
- **Final completion:** —
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018342, "Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01018342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*